New Cancer Med Is Giving Patients Hope, But One Former Senator Says It Comes With A “Nasty” Catch — Live Feedhttps://www.live-feeds.com/feed/new-cancer-med-is-giving-patients-hope-but-one-former-senator-says-it-comes-with-a-nasty-catchContinuously updated, source-cited coverage. FDA Approves Pancreatic Cancer Drug Rasonquehttps://www.live-feeds.com/feed/new-cancer-med-is-giving-patients-hope-but-one-former-senator-says-it-comes-with-a-nasty-catchhttps://www.live-feeds.com/feed/new-cancer-med-is-giving-patients-hope-but-one-former-senator-says-it-comes-with-a-nasty-catch#u52783Mon, 31 Aug 2026 06:06:05 +0000The FDA has approved Rasonque (daraxonrasib), a breakthrough medication designed to treat pancreatic cancer and extend patient lives. Developed by the independent firm RevMed, the drug is described by medical researchers and news outlets as a landmark treatment for an intractable disease. While the approval marks a new era for oncology, the medication carries a monthly list price of $39,800. Early reports indicate the drug has already helped some patients shrink tumors, though concerns remain regarding patient access and affordability.Why it mattersPancreatic cancer is traditionally difficult